Imbria Pharmaceuticals’ Post

Nephrology towards precision medicine through nucleic acid therapeutics! ERA G&K aims to learn how this changes the landscape of patient care in both PH1 and kidney medicine in general. We would like you to contribute and fill the survey (explicitly NOT only but also for PH1 experts): https://bit.ly/433iqVT

#EASL2024 has come to an end. There were significant milestones, including the announcement of clinical results demonstrating excellent clinical efficacy and the listing of the first drug approved for MASH use in clinical guidelines. Above all, it was impressive that the room became solemn as many presenters paid tribute to Dr. Harrison... R.I.P. We would also like to thank the many people who came to see the poster presentation of #DA1241, a first-in-class potential #GPR119 agonist. Please find the poster files if you are interested: [THU-531] Synergistic effect in combo with #Semaglutide in liver #fibrosis mice: https://lnkd.in/g3DFU--M [THU-232] Drastic enhanced anti-MASH effect when combined with #Semaglutide in GAN diet-induced #MASH mice: https://lnkd.in/gcCbzAP7

This World Heart Day, we highlight how pharmacogenomics (PGx) is optimizing cardiovascular treatment. MEDNAwise uses advanced genomic profiling to guide personalized medication strategies. By understanding how your DNA affects drug response, clinicians can tailor treatments for better results and fewer side effects. This innovative approach sets a new standard in personalized heart care. Learn how MEDNAwise can refine your medication strategy for superior cardiovascular care. #WorldHeartDay #Pharmacogenomics #MedicationOptimization #CardiovascularCare #PersonalizedMedicine #knowBetterLiveBetter

Great discussion by Michael Davidson, MD with an overview of their CETPi. Fascinating!

On August 22nd, Alkermes announced the initiation of the Vibrance-2 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with narcolepsy type 2 (NT2). "We are pleased to initiate Vibrance-2, a phase 2 clinical study for adults with narcolepsy type 2, based on the data from our phase 1, proof-of-concept study in this patient population. ALKS 2680 is the most advanced investigational orexin 2 receptor agonist currently in development for narcolepsy type 2," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President, Research & Development at Alkermes. "Across narcolepsy type 1 and narcolepsy type 2, significant unmet need remains, and we look forward to further characterizing the efficacy and safety profile of ALKS 2680 in the Vibrance studies in both of these important patient populations." Read the full article at: https://lnkd.in/eCZBfH_x #narcolepsy #sleepdisorder #phase2 #clinicaltrial #Alkermes

💡 Join Dr. Vince Clinical Research for an upcoming webinar on managing renal and hepatic impairment trials. These trials are essential for assessing the impact of organ impairment on #pharmacokinetics (PK), but recruitment challenges make them more complex than standard clinical studies. Learn how tools like population PK (PopPK) and physiologically based PK (#PBPK) modeling, combined with adaptive trial designs, can reduce patient burden and improve trial outcomes. ➡️ Learn more + register here: https://buff.ly/4gASg2T #ADME #DrugDevelopment #ClinicalResearch #CRO #PatientRecruitment #NASH #NAFLD #TherapeuticAreas #TranslationalResearch #NonalcoholicSteatohepatitis

HOT TAKE: With consensus guidelines for monitoring tacrolimus (2019) and mycophenolate (2021), Europe's by far the leader in advancing SOT individualized care. TL;DR: Mycophenolate MIPD associated with a 2.5-fold lower incidence of graft rejection and improved 3-year rejection-free survival. SOT = solid organ transplant MIPD = model-informed precision dosing The National Library of Medicine (NLM) and PubMed: https://bit.ly/49q89VR | #PrecisionMedicine #ModelInformedPrecisionDosing #PrecisionDosing #TransplantTreatment #MycophenolateMofetil

Hear Dr. Anant Ramaswamy present the DOC-GC study at ASCO GI 2024. The study aimed to determine whether adding docetaxel to standard chemotherapy regimens (FOLFOX or CAPOX) improves survival in patients with advanced gastric and gastroesophageal adenocarcinomas, as well as to assess the usefulness of continuing chemotherapy beyond six months in this group of patients. #ASCOGI24 #Chemotherapy #GastroesophagealAdenocarcinomas

#ESMOGI24: Promising data from the phase III NETTER-2 study show that peptide receptor radionuclide therapy significantly improves outcomes for patients with grade 2 high-grade 3 low gastroenteropancreatic neuroendocrine tumours (GEP-NETs), regardless of tumour grade or primary origin. According to Rocio Garcia-Carbonero, commenting on these results for the #ESMODailyReporter, this study supports the use of 177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs, and possibly selected patients with grade 2 high GEP-NETs. 📌https://ow.ly/aJ9m50Sq7NU

Hear Dr. Anant Ramaswamy present the DOC-GC study at ASCO GI 2024. The study aimed to determine whether adding docetaxel to standard chemotherapy regimens (FOLFOX or CAPOX) improves survival in patients with advanced gastric and gastroesophageal adenocarcinomas, as well as to assess the usefulness of continuing chemotherapy beyond six months in this group of patients. #ASCOGI24 #Chemotherapy #GastroesophagealAdenocarcinomas